Dong Lv
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Dong Lv has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Puze Wang
Department of Urology, People's Hospital of Deyang City, Chengdu University of Traditional Chinese Medicine
3 shared publicationsJing Zheng
Department of Anesthesia and Operating Room, Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China
2 shared publicationsJinze Li
Department of Urology, People's Hospital of Deyang City, Chengdu University of Traditional Chinese Medicine
2 shared publicationsChongzhou Liao
Department of Urology, People's Hospital of Deyang City, Chengdu University of Traditional Chinese Medicine
1 shared publicationDong Ren
Department of Urology, People's Hospital of Deyang City, Chengdu University of Traditional Chinese Medicine
1 shared publicationHuawei Liu
Department of Urology, People's Hospital of Deyang City, Chengdu University of Traditional Chinese Medicine
1 shared publication
Latest Publications
- Open Access
- 14 October 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1946428
MOSES-assisted versus conventional holmium laser enucleation of the prostate for benign prostatic hyperplasia: a pooled study
Purpose: With the widespread adoption of holmium laser enucleation of the prostate (HoLEP), increasing attention has focused on whether pulse-modulation technologies can further improve procedural efficiency and perioperative outcomes. We therefore conducted an updated systematic review and meta-analysis comparing MOSES-assisted HoLEP (MoLEP) with conventional HoLEP for benign prostatic hyperplasia (BPH). Methods: PubMed, Embase, Web of Science, and the ClinicalTrials.gov were searched through September 2026 for comparative studies evaluating MoLEP versus conventional HoLEP. Study selection and data extraction were performed according to predefined criteria. Pooled analyses were conducted using R (version 4.4.1), with subgroup and sensitivity analyses undertaken where appropriate. Results: Ten studies comprising 3,177 patients (1,599 MoLEP and 1,578 conventional HoLEP) were included. MoLEP was associated with shorter enucleation time (MD −7.45 min, 95% CI −11.05 to −3.85; P < 0.001), hemostasis time (MD −3.79 min, 95% CI −5.93 to −1.65; P < 0.001), and operative time (MD −12.09 min, 95% CI −18.01 to −6.18; P < 0.001). No significant between-group differences were observed in enucleated weight (MD 1.01 g, 95% CI −3.20–5.21; P = 0.639), catheterization time (SMD −0.13, 95% CI −0.35–0.09; P = 0.238), or length of stay (SMD −0.23, 95% CI −0.52–0.05; P = 0.113). MoLEP was associated with a generally lower incidence of postoperative complications than conventional HoLEP ( P < 0.001). Regarding functional outcomes, statistically significant between-group differences were observed in PVR at 1 and 6 months, QoL at 3 months, and IPSS at 6 months, whereas other functional outcomes did not differ significantly between groups. Conclusions: The current evidence suggests that MoLEP may improve perioperative efficiency and reduce postoperative complications, while early functional outcomes remain broadly comparable with conventional HoLEP. Further high-quality studies with longer follow-up are needed to confirm these potential benefits. Systematic Review Registration: ID: CRD420251177474.
- 14 October 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1946428
Open AccessMOSES-assisted versus conventional holmium laser enucleation of the prostate for benign prostatic hyperplasia: a pooled study
Purpose: With the widespread adoption of holmium laser enucleation of the prostate (HoLEP), increasing attention has focused on whether pulse-modulation technologies can further improve procedural efficiency and perioperative outcomes. We therefore conducted an updated systematic review and meta-analysis comparing MOSES-assisted HoLEP (MoLEP) with conventional HoLEP for benign prostatic hyperplasia (BPH). Methods: PubMed, Embase, Web of Science, and the ClinicalTrials.gov were searched through September 2026 for comparative studies evaluating MoLEP versus conventional HoLEP. Study selection and data extraction were performed according to predefined criteria. Pooled analyses were conducted using R (version 4.4.1), with subgroup and sensitivity analyses undertaken where appropriate. Results: Ten studies comprising 3,177 patients (1,599 MoLEP and 1,578 conventional HoLEP) were included. MoLEP was associated with shorter enucleation time (MD −7.45 min, 95% CI −11.05 to −3.85; P < 0.001), hemostasis time (MD −3.79 min, 95% CI −5.93 to −1.65; P < 0.001), and operative time (MD −12.09 min, 95% CI −18.01 to −6.18; P < 0.001). No significant between-group differences were observed in enucleated weight (MD 1.01 g, 95% CI −3.20–5.21; P = 0.639), catheterization time (SMD −0.13, 95% CI −0.35–0.09; P = 0.238), or length of stay (SMD −0.23, 95% CI −0.52–0.05; P = 0.113). MoLEP was associated with a generally lower incidence of postoperative complications than conventional HoLEP ( P < 0.001). Regarding functional outcomes, statistically significant between-group differences were observed in PVR at 1 and 6 months, QoL at 3 months, and IPSS at 6 months, whereas other functional outcomes did not differ significantly between groups. Conclusions: The current evidence suggests that MoLEP may improve perioperative efficiency and reduce postoperative complications, while early functional outcomes remain broadly comparable with conventional HoLEP. Further high-quality studies with longer follow-up are needed to confirm these potential benefits. Systematic Review Registration: ID: CRD420251177474.
- Open Access
- 17 June 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1592066
A comprehensive overview of triptolide utilizing nanotechnology and its potential applications in prostate diseases
Triptolide (TPL) demonstrates a broad spectrum of biological and pharmacological activities, with its primary effects encompassing anti-inflammatory and anti-tumor properties, thereby rendering it applicable in the treatment of various diseases. However, the toxicity associated with TPL has considerably limited its clinical application. In recent years, the advancement of functional nanotechnology has created new opportunities for the application of TPL. TPL has been formulated using nanotechnology, resulting in a stable and tightly bound preparation. Regarding nanoparticle release, TPL can rapidly release the drug in acidic environments, such as tumor tissues, through pH-sensitive nanoparticles, while releasing the drug slowly under normal pH conditions. Furthermore, the surface characteristics and particle size of the carrier can be adjusted to control the drug release rate, thereby enhancing efficacy and reducing side effects. In terms of nanotargeting, active targeting achieved through surface modification can increase the concentration of the drug at the lesion site. Nanotechnology enhances the effectiveness of TPL, underscores its clinical advantages and potential, improves its disease-related performance, and offers novel strategies for disease treatment. This strategy is essential for improving therapeutic efficacy while minimizing side effects and enhancing bioavailability. Nano-TPL exhibits considerable potential for clinical application, owing to its effective targeted anti-inflammatory and anti-tumor properties, as well as its minimal toxic side effects. In this review, we present a succinct summary of the pharmacological activities and adverse effects of TPL, modifications made to its delivery system via nanotechnology, and its clinical application prospect is exemplified by prostate disease.
- 17 June 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1592066
Open AccessA comprehensive overview of triptolide utilizing nanotechnology and its potential applications in prostate diseases
Triptolide (TPL) demonstrates a broad spectrum of biological and pharmacological activities, with its primary effects encompassing anti-inflammatory and anti-tumor properties, thereby rendering it applicable in the treatment of various diseases. However, the toxicity associated with TPL has considerably limited its clinical application. In recent years, the advancement of functional nanotechnology has created new opportunities for the application of TPL. TPL has been formulated using nanotechnology, resulting in a stable and tightly bound preparation. Regarding nanoparticle release, TPL can rapidly release the drug in acidic environments, such as tumor tissues, through pH-sensitive nanoparticles, while releasing the drug slowly under normal pH conditions. Furthermore, the surface characteristics and particle size of the carrier can be adjusted to control the drug release rate, thereby enhancing efficacy and reducing side effects. In terms of nanotargeting, active targeting achieved through surface modification can increase the concentration of the drug at the lesion site. Nanotechnology enhances the effectiveness of TPL, underscores its clinical advantages and potential, improves its disease-related performance, and offers novel strategies for disease treatment. This strategy is essential for improving therapeutic efficacy while minimizing side effects and enhancing bioavailability. Nano-TPL exhibits considerable potential for clinical application, owing to its effective targeted anti-inflammatory and anti-tumor properties, as well as its minimal toxic side effects. In this review, we present a succinct summary of the pharmacological activities and adverse effects of TPL, modifications made to its delivery system via nanotechnology, and its clinical application prospect is exemplified by prostate disease.
- Open Access
- 18 December 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1483855
Prognostic significance of hemoglobin, albumin, lymphocyte and platelet score in solid tumors: a pooled study
Objective: The high hemoglobin, albumin, lymphocyte, and platelet (HALP) score has been reported to be a good prognostic indicator for several malignancies. However, more evidence is needed before it can be introduced into clinical practice. Here, we systematically evaluated the predictive value of HALP for survival outcomes in patients with solid tumors. Methods: This study was performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and Assessing the Methodological Quality of Systematic Reviews (AMSTAR) Guidelines. In March 2024, an electronic literature search was performed for articles regarding the prognostic role of HALP in solid tumors. Data from studies with reported risk ratios (HRs) and 95% confidence intervals (CIs) were pooled in a meta-analysis. Study bias was assessed using the QUIPS tool. Results: Of the 729 articles reviewed, 45 cohorts including data from 17,049 patients with cancer were included in the pooled analysis. The pooled results demonstrated that elevated HALP score was significantly associated with favorable overall survival (HR = 0.60, 95% CI 0.54-0.67, p < 0.01), cancer-specific survival (HR = 0.53, 95% CI 0.44- 0.64, p < 0.01), progression-free survival (HR = 0.62, 95% CI 0.54-0.72, p < 0.01), recurrence-free survival (HR = 0.48, 95% CI 0.30-0.77, p < 0.01), and disease-free survival (HR = 0.72, 95% CI 0.57-0.82, p < 0.01). Subgroup analyses based on various confounding factors further revealed the consistent prognostic impact of HALP on overall survival in patients with solid tumors. Conclusions: Our findings suggest that high HALP is associated with better survival outcomes in patients. The HALP score is a potential prognostic biomarker in solid tumors, but it needs to be further studied whether it can improve the established prognostic model.
- 18 December 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1483855
Open AccessPrognostic significance of hemoglobin, albumin, lymphocyte and platelet score in solid tumors: a pooled study
Objective: The high hemoglobin, albumin, lymphocyte, and platelet (HALP) score has been reported to be a good prognostic indicator for several malignancies. However, more evidence is needed before it can be introduced into clinical practice. Here, we systematically evaluated the predictive value of HALP for survival outcomes in patients with solid tumors. Methods: This study was performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and Assessing the Methodological Quality of Systematic Reviews (AMSTAR) Guidelines. In March 2024, an electronic literature search was performed for articles regarding the prognostic role of HALP in solid tumors. Data from studies with reported risk ratios (HRs) and 95% confidence intervals (CIs) were pooled in a meta-analysis. Study bias was assessed using the QUIPS tool. Results: Of the 729 articles reviewed, 45 cohorts including data from 17,049 patients with cancer were included in the pooled analysis. The pooled results demonstrated that elevated HALP score was significantly associated with favorable overall survival (HR = 0.60, 95% CI 0.54-0.67, p < 0.01), cancer-specific survival (HR = 0.53, 95% CI 0.44- 0.64, p < 0.01), progression-free survival (HR = 0.62, 95% CI 0.54-0.72, p < 0.01), recurrence-free survival (HR = 0.48, 95% CI 0.30-0.77, p < 0.01), and disease-free survival (HR = 0.72, 95% CI 0.57-0.82, p < 0.01). Subgroup analyses based on various confounding factors further revealed the consistent prognostic impact of HALP on overall survival in patients with solid tumors. Conclusions: Our findings suggest that high HALP is associated with better survival outcomes in patients. The HALP score is a potential prognostic biomarker in solid tumors, but it needs to be further studied whether it can improve the established prognostic model.